Suppr超能文献

单次就诊方案在体外受精后不明位置妊娠管理中的应用:一项回顾性研究。

Development of a single-visit protocol for the management of pregnancy of unknown location following in vitro fertilization: a retrospective study.

机构信息

Faculty of Population Health Sciences, Institute for Women's Health, University College Hospital, London, UK.

Early Pregnancy and Gynaecology Assessment Unit, Kings College Hospital, London, UK.

出版信息

Hum Reprod. 2024 Mar 1;39(3):509-515. doi: 10.1093/humrep/deae002.

Abstract

STUDY QUESTION

Can women with pregnancy of unknown location (PUL) following in vitro fertilization (IVF) be risk-stratified regarding the subsequent need for medical intervention, based on their demographic characteristics and the results of serum biochemistry at the initial visit?

SUMMARY ANSWER

The ratio of serum hCG to number of days from conception (hCG/C) or the initial serum hCG level at ≥5 weeks' gestation could be used to estimate the risk of women presenting with PUL following IVF and needing medical intervention during their follow-up.

WHAT IS KNOWN ALREADY

In women with uncertain conception dates presenting with PUL, a single serum hCG measurement cannot be used to predict the final pregnancy outcomes, thus, serial levels are mandatory to establish a correct diagnosis. Serum progesterone levels can help to risk-stratify women at their initial visit but are not accurate in those taking progesterone supplementation, such as women pregnant following IVF.

STUDY DESIGN, SIZE, DURATION: This was a retrospective study carried out at two specialist early pregnancy assessment units between May 2008 and January 2021. A total of 224 women met the criteria for inclusion, but 14 women did not complete the follow-up and were excluded from the study.

PARTICIPANTS/MATERIALS, SETTING, METHODS: We selected women who had an IVF pregnancy and presented with PUL at ≥5 weeks' gestation.

MAIN RESULTS AND THE ROLE OF CHANCE

A total of 30/210 (14.0%, 95% CI 9.9-19.8) women initially diagnosed with PUL required surgical intervention. The hCG/C was significantly higher in the group of women requiring an intervention compared to those who did not (P = 0.003), with an odds ratio of 3.65 (95% CI 1.49-8.89, P = 0.004). A hCG/C <4.0 was associated with a 1.9% risk of intervention, which accounted for 25.7% of the study population. A similar result was obtained by substituting hCG/C <4.0 with an initial hCG level <100 IU/l, which was associated with 2.0% risk of intervention, and accounted for 23.8% of the study population (P > 0.05).

LIMITATIONS, REASONS FOR CAUTION: A limitation of our study is that it is retrospective in nature, and as such, we were reliant on existing data.

WIDER IMPLICATIONS OF THE FINDINGS

A previous study in women with PUL after spontaneous conception found that a 2% intervention rate was considered low enough to eliminate the need for close follow-up and serial blood tests. Using the same 2% cut-off, a quarter of women with PUL after IVF could also avoid attending for further visits and investigations.

STUDY FUNDING/COMPETING INTEREST(S): No external funding was required for this study. No conflicts of interest are required to be declared.

TRIAL REGISTRATION NUMBER

N/A.

摘要

研究问题

对于接受体外受精(IVF)后妊娠位置不明(PUL)的女性,能否根据其人口统计学特征和初次就诊时的血清生化结果对后续需要医疗干预的风险进行分层?

总结答案

血清 hCG 与受孕天数(hCG/C)的比值或≥5 周妊娠时的初始血清 hCG 水平可用于估计 IVF 后出现 PUL 并在随访期间需要医疗干预的女性的风险。

已知情况

对于不确定受孕日期的 PUL 女性,单次血清 hCG 测量不能用于预测最终妊娠结局,因此需要进行连续检测以做出正确诊断。血清孕激素水平有助于在初次就诊时对女性进行风险分层,但对于接受孕激素补充的女性(如接受 IVF 受孕的女性)并不准确。

研究设计、规模、持续时间:这是一项 2008 年 5 月至 2021 年 1 月在两个专科早孕评估单位进行的回顾性研究。共有 224 名女性符合纳入标准,但有 14 名女性未完成随访,被排除在研究之外。

参与者/材料、地点、方法:我们选择了接受 IVF 妊娠且在≥5 周妊娠时出现 PUL 的女性。

主要结果和机会作用

共有 30/210(14.0%,95%CI 9.9-19.8)名最初诊断为 PUL 的女性需要手术干预。与未接受干预的女性相比,需要干预的女性 hCG/C 明显更高(P=0.003),优势比为 3.65(95%CI 1.49-8.89,P=0.004)。hCG/C<4.0 与 1.9%的干预风险相关,占研究人群的 25.7%。用 hCG/C<4.0 替代初始 hCG 水平<100IU/l 也得到了类似的结果,其干预风险为 2.0%,占研究人群的 23.8%(P>0.05)。

局限性、谨慎的原因:本研究的一个局限性是它是回顾性的,因此我们依赖于现有数据。

研究结果的更广泛意义

一项针对自然受孕后 PUL 女性的先前研究发现,2%的干预率被认为足够低,可以消除密切随访和连续血液检查的需要。使用相同的 2%截断值,四分之一的 IVF 后 PUL 女性也可以避免进一步就诊和检查。

研究资金/利益冲突:本研究无需外部资金。无需申报利益冲突。

试验注册编号

无。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验